Prof. Klusmann was honored with the election to be chair of the AML-BFM study group leading future studies to improve outcomes of pediatric patients with AML. In Frankfurt, a dedicated team is ready to move forward- combining state-of-the-art diagnostics, expert consultation and innovative translational research. Together the team will design and implement the next generation of precision-driven, impactful clinical trials.